Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART

被引:23
作者
Pacheco, Yolanda M. [1 ]
Jarrin, Inmaculada [2 ]
Del Amo, Julia [2 ,3 ]
Moreno, Santiago [4 ,5 ]
Iribarren, Jose A. [6 ]
Viciana, Pompeyo [1 ]
Parra, Jorge [7 ]
Gomez-Sirvent, Juan L. [8 ]
Gutierrez, Felix [9 ]
Blanco, Jose R. [10 ]
Vidal, Francesc [11 ]
Leal, Manuel [1 ]
机构
[1] Hosp Univ Virgen del Rocio, Serv Enfermedades Infecciosas, Seville 41013, Spain
[2] Inst Salud Carlos III, Madrid, Spain
[3] Univ Rey Juan Carlos I, Madrid, Spain
[4] Hosp Ramon & Cajal, Madrid, Spain
[5] Univ Alcala de Henares, Madrid, Spain
[6] Hosp Donostia, San Sebastian, Spain
[7] Hosp Clin Univ San Cecilio, Granada, Spain
[8] Hosp Univ Canarias, Tenerife, Spain
[9] Univ Miguel Hernandez, Hosp Univ Elche, Alicante, Spain
[10] Hosp San Pedro, Logrono, Spain
[11] Univ Rovira & Virgili, Hosp Univ Joan XXIII, Tarragona, Spain
关键词
CD4; counts; restoration; HAART; cohort; risk factors and mortality; COMBINATION ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL-ACTIVATION; DISCORDANT RESPONSES; VIRAL SUPPRESSION; THYMIC VOLUME; AIDS; INDIVIDUALS; INCREASES; AGE;
D O I
10.2174/157016209789973673
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A proportion of HIV-patients does not normally restore their CD4 counts despite virological response to HAART. Those whose CD4 counts persistently remain closed to the critical threshold for opportunistic infections deserve special interest. To study the risk factors, the long-term CD4 counts evolution, and the risk of death of patients who persistently maintain low CD4 counts, despite virological response to HAART, within a multicenter, hospital-based cohort study. A total of 147 patients were selected from CoRIS- MD and classified into a "Low-Group" or a "High-Group", depending on their CD4 counts after two-years of effective HAART (threshold 250 cells/mu L). Associated risk factors were analysed by logistic regression, the CD4 dynamics were evaluated over a total period of 7.70 years (IQR, 6.70-9.00), and mortality was estimated by Cox proportional hazard. A total of 40 patients (27%) were classified into the "Low-Group". The odds ratio for this group increased with age, being 4.56 (2.23-9.33) for over 40, and was also higher among IDU, 3.63 (1.04-12.68). Six years thereafter, among these patients, only a 30% exceeded 350 CD4 cells/mu L and a 12% exceeded 500 CD4 cells/mu L. Furthermore, the "Low-Group" had a death rate of 2.42 per 100 persons/year (95% CI, 1.01-5.81), although once adjusted by age the estimates were no longer significant [4.14 (0.87-19.72)]. Our results suggest that those HIV patients who have not overcome the critical threshold of 250 CD4 cells/mu L after a two years period of virologically effective HAART do persist with the aforementioned failure of CD4 restoration for a much longer time.
引用
收藏
页码:612 / 619
页数:8
相关论文
共 39 条
[1]   Poor initial CD4+recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases [J].
Baker, Jason V. ;
Peng, Grace ;
Rapkin, Joshua ;
Krason, David ;
Reilly, Cavan ;
Cavert, Winston P. ;
Abrams, Donald I. ;
MacArthur, Rodger D. ;
Henry, Keith ;
Neaton, James D. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 48 (05) :541-546
[2]   CD4+count and risk of non-AIDS diseases following initial treatment for HIV infection [J].
Baker, Jason V. ;
Peng, Grace ;
Rapkin, Joshua ;
Abrams, Donald I. ;
Silverberg, Michael J. ;
MacArthur, Rodger D. ;
Cavert, Winston P. ;
Henry, W. Keith ;
Neaton, James D. .
AIDS, 2008, 22 (07) :841-848
[3]   Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads [J].
Benveniste, O ;
Flahault, A ;
Rollot, F ;
Elbim, C ;
Estaquier, J ;
Pédron, B ;
Duval, X ;
Dereuddre-Bosquet, N ;
Clayette, P ;
Sterkers, G ;
Simon, A ;
Ameisen, JC ;
Leport, C .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (10) :1670-1679
[4]   Drugs of Abuse, Immune Modulation, and AIDS [J].
Cabral, Guy A. .
JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2006, 1 (03) :280-295
[5]  
Chene G, 2003, LANCET, V362, P679, DOI 10.1016/S0140-6736(03)14229-8
[6]   Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy [J].
Delobel, Pierre ;
Nugeyre, Marie-Therese ;
Cazabat, Michelle ;
Sandres-Saune, Karine ;
Pasquier, Christophe ;
Cuzin, Lise ;
Marchou, Bruno ;
Massip, Patrice ;
Cheynier, Remi ;
Barre-Sinoussi, Francoise ;
Izopet, Jacques ;
Israel, Nicole .
JOURNAL OF VIROLOGY, 2006, 80 (20) :10229-10236
[7]   Changes in thymic function with age and during the treatment of HIV infection [J].
Douek, DC ;
McFarland, RD ;
Keiser, PH ;
Gage, EA ;
Massey, JM ;
Haynes, BF ;
Polis, MA ;
Haase, AT ;
Feinberg, MB ;
Sullivan, JL ;
Jamieson, BD ;
Zack, JA ;
Picker, LJ ;
Koup, RA .
NATURE, 1998, 396 (6712) :690-695
[8]   Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression [J].
Dronda, F ;
Moreno, S ;
Moreno, A ;
Casado, JL ;
Pérez-Elías, MJ ;
Antela, A .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (08) :1005-1009
[9]   Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function [J].
Fernandez, Sonia ;
Price, Patricia ;
McKinnon, Elizabeth J. ;
Nolan, Richard C. ;
French, Martyn A. .
CLINICAL IMMUNOLOGY, 2006, 120 (02) :163-170
[10]  
Florence E, 2003, HIV Med, V4, P255, DOI 10.1046/j.1468-1293.2003.00156.x